Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francois Ghiringhelli

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Cancer Research|November 6, 2025
Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T Cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite Stable Colorectal CancerJean-David Fumet, Charlène Latour, Lisa Nuttin, et al.
Cancer Immunology, Immunotherapy : CII|August 21, 2022
Interplay between plasmacytoid dendritic cells and tumor-specific T cells in peripheral blood influences long-term survival in non-small cell lung carcinomaCaroline Laheurte, Evan Seffar, Eléonore Gravelin, et al.
Oncotarget|August 4, 2016
Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastomaAurélie Bertaut, Caroline Truntzer, Rachid Madkouri, et al.
Frontiers in Oncology|August 8, 2024
Efficacy of novel allogeneic cancer cells vaccine to treat colorectal cancerGeorge Alzeeb, Corinne Tortorelli, Jaqueline Taleb, et al.
Future Oncology (London, England)|February 6, 2025
FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trialHélène Bellio, Nicolas Roussot, Aurélie Bertaut, et al.
Gut|July 13, 2021
<i>Helicobacter pylori</i> infection has a detrimental impact on the efficacy of cancer immunotherapiesPaul Oster, Laurie Vaillant, Erika Riva, et al.
Annals of Surgical Oncology|January 15, 2014
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resectionFrancois Ghiringhelli, Damien Bichard, Samuel Limat, et al.
Frontiers in Oncology|December 26, 2025
Cancer-associated fibroblasts and their prognostic role in colorectal cancer: review and meta-analysisSilvia Mihaela Ilie, Laurentia Gales, Ana Maria Musina, et al.
Journal for Immunotherapy of Cancer|January 16, 2026
Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytesEmma Groetz, Sabrina Perrey, Alvaro Baeza Garcia, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 14, 2015
FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802)Thomas Aparicio, Benjamin Linot, Karine Le Malicot, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Cancer Research|November 6, 2025
Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T Cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite Stable Colorectal CancerJean-David Fumet, Charlène Latour, Lisa Nuttin, et al.
Cancer Immunology, Immunotherapy : CII|August 21, 2022
Interplay between plasmacytoid dendritic cells and tumor-specific T cells in peripheral blood influences long-term survival in non-small cell lung carcinomaCaroline Laheurte, Evan Seffar, Eléonore Gravelin, et al.
Oncotarget|August 4, 2016
Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastomaAurélie Bertaut, Caroline Truntzer, Rachid Madkouri, et al.
Frontiers in Oncology|August 8, 2024
Efficacy of novel allogeneic cancer cells vaccine to treat colorectal cancerGeorge Alzeeb, Corinne Tortorelli, Jaqueline Taleb, et al.
Future Oncology (London, England)|February 6, 2025
FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trialHélène Bellio, Nicolas Roussot, Aurélie Bertaut, et al.
Gut|July 13, 2021
<i>Helicobacter pylori</i> infection has a detrimental impact on the efficacy of cancer immunotherapiesPaul Oster, Laurie Vaillant, Erika Riva, et al.
Annals of Surgical Oncology|January 15, 2014
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resectionFrancois Ghiringhelli, Damien Bichard, Samuel Limat, et al.
Frontiers in Oncology|December 26, 2025
Cancer-associated fibroblasts and their prognostic role in colorectal cancer: review and meta-analysisSilvia Mihaela Ilie, Laurentia Gales, Ana Maria Musina, et al.
Journal for Immunotherapy of Cancer|January 16, 2026
Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytesEmma Groetz, Sabrina Perrey, Alvaro Baeza Garcia, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 14, 2015
FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802)Thomas Aparicio, Benjamin Linot, Karine Le Malicot, et al.
Pageof 10